Relative hazard to achieve viro-immunological response according to baseline FPR ranks in HIV-1 infected patients starting their first-line HAART (Cox Models).

a. Adjusted for: age, gender, risk factor, pre-HAART CD4 cell count, pre-HAART HIV-RNA, hepatitis C coinfection, year of starting treatment, transmitted drug resistance, third drug used (non-nucleoside reverse transcriptase inhibitor vs. boosted protease inhibitor vs. raltegravir), NRTI backbone used, number of drug administered (≤3 vs. >3 drugs); b. Reference group (dummy); Boldface indicates the geno2pheno false positive rate (FPR) ranks that were significantly associated (p<0.05) with viro-immunological response. C.I.: confidence interval.